100 related articles for article (PubMed ID: 11378569)
1. Activating mutations of c-kit at codon 816 confer drug resistance in human leukemia cells.
Ning ZQ; Li J; Arceci RJ
Leuk Lymphoma; 2001 May; 41(5-6):513-22. PubMed ID: 11378569
[TBL] [Abstract][Full Text] [Related]
2. STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity.
Ning ZQ; Li J; McGuinness M; Arceci RJ
Oncogene; 2001 Jul; 20(33):4528-36. PubMed ID: 11494148
[TBL] [Abstract][Full Text] [Related]
3. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells.
Ning ZQ; Li J; Arceci RJ
Blood; 2001 Jun; 97(11):3559-67. PubMed ID: 11369651
[TBL] [Abstract][Full Text] [Related]
4. Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis.
Hassan HT; Zander A
Acta Haematol; 1996; 95(3-4):257-62. PubMed ID: 8677752
[TBL] [Abstract][Full Text] [Related]
5. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation.
Beghini A; Cairoli R; Morra E; Larizza L
Blood Cells Mol Dis; 1998 Jun; 24(2):262-70. PubMed ID: 9714703
[TBL] [Abstract][Full Text] [Related]
6. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts.
Smolich BD; Yuen HA; West KA; Giles FJ; Albitar M; Cherrington JM
Blood; 2001 Mar; 97(5):1413-21. PubMed ID: 11222388
[TBL] [Abstract][Full Text] [Related]
7. Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells.
Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
Clin Cancer Res; 2001 Dec; 7(12):3884-93. PubMed ID: 11751479
[TBL] [Abstract][Full Text] [Related]
8. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
9. A novel c-kit positive biphenotypic acute leukemia cell line, TMBL-1, carrying a p53 point mutation.
Suzuki S; Uozumi K; Hanada S; Lin XY; Ohno N; Takatsuka Y; Takeuchi S; Owatari S; Takeshita T; Arima T
Leuk Lymphoma; 2003 May; 44(5):849-57. PubMed ID: 12802925
[TBL] [Abstract][Full Text] [Related]
10. Implication of tyrosine kinase receptor and steel factor in cell density-dependent growth in cervical cancers and leukemias.
Caceres-Cortes JR; Alvarado-Moreno JA; Waga K; Rangel-Corona R; Monroy-Garcia A; Rocha-Zavaleta L; Urdiales-Ramos J; Weiss-Steider B; Haman A; Hugo P; Brousseau R; Hoang T
Cancer Res; 2001 Aug; 61(16):6281-9. PubMed ID: 11507083
[TBL] [Abstract][Full Text] [Related]
11. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
[TBL] [Abstract][Full Text] [Related]
12. Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5.
Le Gall M; Crépin R; Neiveyans M; Auclair C; Fan Y; Zhou Y; Marks JD; Pèlegrin A; Poul MA
Mol Cancer Ther; 2015 Nov; 14(11):2595-605. PubMed ID: 26358753
[TBL] [Abstract][Full Text] [Related]
13. CS-1, a novel c-kithi+ acute myeloid leukemia cell line with dendritic cell differentiation capacity and absent immunogenicity.
Erben U; Thiel E; Bittroff-Leben A; Schoch C; Fichtner I; Dürkop H; Notter M
Int J Cancer; 2003 Jun; 105(2):232-40. PubMed ID: 12673685
[TBL] [Abstract][Full Text] [Related]
14. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
15. Effects of stem cell factor on the growth and radiation survival of tumor cells.
Shui C; Khan WB; Leigh BR; Turner AM; Wilder RB; Knox SJ
Cancer Res; 1995 Aug; 55(15):3431-7. PubMed ID: 7542170
[TBL] [Abstract][Full Text] [Related]
16. C-kit receptors in childhood malignant lymphoblastic cells.
Sykora KW; Tomeczkowski J; Reiter A
Leuk Lymphoma; 1997 Apr; 25(3-4):201-16. PubMed ID: 9168431
[TBL] [Abstract][Full Text] [Related]
17. Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia.
Beghini A; Magnani I; Ripamonti CB; Larizza L
Hematol J; 2002; 3(3):157-63. PubMed ID: 12111653
[TBL] [Abstract][Full Text] [Related]
18. Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate.
Kosmider O; Denis N; Dubreuil P; Moreau-Gachelin F
Oncogene; 2007 May; 26(26):3904-8. PubMed ID: 17173066
[TBL] [Abstract][Full Text] [Related]
19. Cooperation of MLL/AF10(OM-LZ) with PTPN11 activating mutation induced monocytic leukemia with a shorter latency in a mouse bone marrow transplantation model.
Fu JF; Liang ST; Huang YJ; Liang KH; Yen TH; Liang DC; Shih LY
Int J Cancer; 2017 Mar; 140(5):1159-1172. PubMed ID: 27859216
[TBL] [Abstract][Full Text] [Related]
20. Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression.
Herrmann MD; Lennerz JK; Bullinger L; Bartholomae S; Holzmann K; Westhoff MA; Corbacioglu S; Debatin KM
Exp Hematol; 2014 Feb; 42(2):90-100. PubMed ID: 24211243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
